Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
机构：[1]Clinical Oncology, Prince of Wales Hospital, Hong Kong, China,[2]Jilin Provincial CancerHospital, Changchun, China,[3]Department of Respiratory Medicine, First AffiliatedHospital of Third Military Medical University, Chongqing, China,[4]Chungbuk NationalUniversity College of Medicine, Chungbuk National University Hospital, Cheongju,Republic of Korea,[5]Kindai University Hospital, Osaka, Japan,[6]Department of ThoracicOncology, National Cancer Center Hospital East, Kashiwa, Japan,[7]SFJPharmaceuticalsVR , Pleasanton, CA, USA,[8]Catalan Institute of Oncology, Barcelona,Spain,[9]Hospital Universitario Virgen del Rocio, Seville, Spain,[10]Pulmonary OncologyUnit, San Camillo-Forlanini Hospital, Rome, Italy,[11]The Maria Sklodowska-CurieMemorial Cancer Centre and Institute of Oncology, Warsaw, Poland,[12]Pfizer Inc.,Groton, CT, USA,[13]Pfizer Oncology, La Jolla, CA, USA,[14]Guangdong Lung CancerInstitute, Guangdong Provincial People’s Hospital and Guangdong Academy of MedicalSciences, Guangzhou, China
第一作者机构：[1]Clinical Oncology, Prince of Wales Hospital, Hong Kong, China,
推荐引用方式(GB/T 7714)：
T.S.K. Mok,Y. Cheng,X. Zhou,et al.Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations[J].ANNALS OF ONCOLOGY.2019,30:
APA：
T.S.K. Mok,Y. Cheng,X. Zhou,K.H. Lee,K. Nakagawa...&Y-L. Wu.(2019).Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations.ANNALS OF ONCOLOGY,30,
MLA：
T.S.K. Mok,et al."Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations".ANNALS OF ONCOLOGY 30.(2019)
医学